CClinicalTrials.gg
CompletedNCT03458754Updated Nov 24, 2020

Maximal Exercise Capacity, Physical Activity and Respiratory Muscle Strength in Peripheral Artery Disease

An observational study in Peripheral Arterial Disease, sponsored by Gazi University. Completed at 2 sites in Turkey. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by Gazi University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
35
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The primary aim of the study is to evaluate the maximal and submaximal exercise capacity in patients with peripheral artery disease (PAD). The secondary aim of the study is assessment of physical activity level, respiratory function, peripheral and respiratory muscle strength, respiratory muscle endurance, depression, quality of life, intermittent claudication and cardiovascular risk factors in patients with PAD.

Read the detailed description

Peripheral artery disease is characterized by reduced exercise capacity, physical activity level and intermittent claudication. The number of studies investigating maximal and submaximal exercise capacity and physical activity level in PAD is limited. There is also no study investigated pulmonary functions, respiratory muscle strength and endurance in this patient population. According to the sample size analysis 15 patients and 15 healthy individuals with similar demographic characteristics will be included the study. Patients and healthy individuals will be selected according to predetermined inclusion and exclusion criteria. The assessments will be completed in two days.Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)

02

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • Peripheral Arterial Disease
  • Exercise capacity
  • Physical activity
  • Respiratory muscle strength
  • Peripheric muscle strength
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

At least 15 patients with PAD will be included in patients group and 15 healthy individuals will be included in control group

Inclusion criteria

Patients;

  • Diagnosed with peripheral artery disease
  • Ankle brachial index (ABI)≤ 1,5 or calcified vessel response
  • Clinically stable and under standard medication patients will be included

Exclusion criteria

Exclusion Criteria:

Patients with;

  • Ischemic amputation
  • Any pulmonary disease
  • Unstable coronary artery disease
  • Orthopedic and neurological problems
  • Acute infection
  • Myocardial infarction or major surgery in the last 3 months will be excluded

Healthy controls: Ages 18-80 years will be included

  • With any diagnosed disease and smoking more than 10 packsyears will be excluded
04

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
35 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients

    Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)

  • Healthy controls

    Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)

05

What researchers measure

Primary outcomes

  1. Maximal exercise capacity

    Cardiopulmonary exercise testing (Oxygen consumption measurement during test)

    Time frame: First day

Secondary outcomes

  1. Functional exercise capacity

    Six minute stepper test

    Time frame: Second day

  2. Physical activity

    Multi sensor activity monitor

    Time frame: Second day

  3. Pulmonary function

    Spirometry

    Time frame: First day

  4. Respiratory muscle strength

    Mouth pressure device

    Time frame: First day

  5. Peripheral muscle strength

    Hand held dynamometer

    Time frame: Second day

  6. Respiratory muscle endurance

    Incremental threshold loading test

    Time frame: Second day

  7. Depression

    Beck depression inventory (Turkish version)

    Time frame: Second day

  8. Life quality

    SF-36 Health Survey (Turkish version)

    Time frame: Second day

  9. Intermittent claudication

    Walking Impairment Questionnaire (Turkish version)

    Time frame: Second day

06

Study locations

2 sites
  • Gazi University
    Ankara, 06500, Turkey
  • Gazi University Faculty of Health Sciences Department of Physical Therapy and Rehabilitation
    Yenimahalle, Turkey
07

References and documents

Publications

  • Leeper NJ, Myers J, Zhou M, Nead KT, Syed A, Kojima Y, Caceres RD, Cooke JP. Exercise capacity is the strongest predictor of mortality in patients with peripheral arterial disease. J Vasc Surg. 2013 Mar;57(3):728-33. doi: 10.1016/j.jvs.2012.07.051. Epub 2012 Oct 6. PubMed 23044259 ↗
  • Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011 Jul 5;124(1):17-23. doi: 10.1161/CIRCULATIONAHA.110.003954. Epub 2011 Jun 20. PubMed 21690489 ↗
  • Nordanstig J, Broeren M, Hensater M, Perlander A, Osterberg K, Jivegard L. Six-minute walk test closely correlates to "real-life" outdoor walking capacity and quality of life in patients with intermittent claudication. J Vasc Surg. 2014 Aug;60(2):404-9. doi: 10.1016/j.jvs.2014.03.003. Epub 2014 Mar 29. PubMed 24690492 ↗
  • Colas-Ribas C, Signolet I, Henni S, Feuillloy M, Gagnadoux F, Abraham P. High prevalence of known and unknown pulmonary diseases in patients with claudication during exercise oximetry: A retrospective analysis. Medicine (Baltimore). 2016 Oct;95(40):e4888. doi: 10.1097/MD.0000000000004888. PubMed 27749546 ↗
  • Sieminski DJ, Gardner AW. The relationship between free-living daily physical activity and the severity of peripheral arterial occlusive disease. Vasc Med. 1997 Nov;2(4):286-91. doi: 10.1177/1358863X9700200402. PubMed 9575600 ↗
  • Gardner AW, Montgomery PS, Scott KJ, Blevins SM, Afaq A, Nael R. Association between daily ambulatory activity patterns and exercise performance in patients with intermittent claudication. J Vasc Surg. 2008 Nov;48(5):1238-44. doi: 10.1016/j.jvs.2008.06.062. Epub 2008 Sep 4. PubMed 18771878 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03458754
Lead sponsor
Gazi University
Responsible party
Meral Boşnak Güçlü (Assoc. Prof, Gazi University) — Principal investigator
First posted
Mar 8, 2018
Start date
Jan 1, 2018
Primary completion
Dec 31, 2018
Completion
Mar 31, 2019
Last update
Nov 24, 2020

Study contacts

İnci Hazal Ayas, MSc
study chair · Gazi University
Meral Boşnak Güçlü, Assoc. Prof
study director · Gazi University
Burcu Camcıoğlu, PhD
principal investigator · Gazi University
Dilek Erer, MD
principal investigator · Gazi University
Abdullah Özer, MD
principal investigator · Gazi University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion